ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
ACTUATE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.60−0.01 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $14.30M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$6.8810 (−91.99%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $14.30M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 14.46
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$20.45M
- EPS, diluted
- -$0.88
- Book value per share
- $0.04
- Diluted shares
- 24M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$20.77M
Net income
-$20.45M
EPS, diluted
-$0.88
Reported periodTrailing twelve months